No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $32
Intellia Begins Phase 3 Trial for CRISPR Gene Therapy Targeting Rare Nerve Disease
Express News | Intellia Therapeutics Inc: Plans to Submit a Biologics Licensing Application for Attrv-Pn by 2028
RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk
Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?
Cantor Analysts Call for RFK Jr. Replacement Following Ousting of Marks at FDA
